Is an electronic signature legally valid?

Yes. Under the federal ESIGN Act (15 U.S.C. §7001) and state UETA laws, electronic signatures are generally enforceable provided intent, consent, attribution, and record retention are satisfied. Exceptions include wills, certain court filings, and other statutory exclusions listed by federal or state law.

Who may sign on behalf of a corporation?

Authorized officers or representatives with properly documented corporate authority may sign; execute under board resolution, corporate bylaws, or power of attorney where required. Verify signer authority in the fillable fields and retain evidence of authorization to avoid invalidation challenges.

Do I need a notary or witnesses?

Not normally for most license agreements, but notarization or witnesses may be required by state law for certain instrument types, or to record property interests. Check state-specific notarization and witness rules; use RON where permitted and retain recording as required.

How do electronic signatures satisfy HIPAA?

Electronic signatures can meet HIPAA requirements when used within HIPAA-compliant workflows and a Business Associate Agreement (BAA) is in place. Ensure encryption, access controls, and retention policies meet 45 CFR §164.530(j) requirements and that PHI disclosures are authorized.

What happens if a signer name is incorrect?

A mismatched or incorrect signer name can create enforceability questions or trigger requests for re-execution. Verify full legal names in the fillable fields, attach corporate authority if needed, and use signer authentication to strengthen attribution and reduce dispute risk.

How do I amend the agreement later?

Use a written amendment signed by authorized representatives referencing the original agreement and effective date. Document changes clearly, update schedules, and retain both the amendment and prior versions per retention policy to preserve auditability and demonstrate consent to modifications.

Electronic Signature
Templates
Other
License Agreement by and between Casi Pharmaceuticals Inc

License Agreement by and between Casi Pharmaceuticals Inc

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

What the License Agreement by and between Casi Pharmaceuticals Inc Covers

The License Agreement by and between Casi Pharmaceuticals Inc is a legal contract that grants rights to use, develop, or commercialize specified intellectual property, technology, or pharmaceutical compounds under defined terms and conditions. It allocates rights and obligations including scope of license, exclusivity, territory, sublicensing, royalty structure, diligence obligations, confidentiality, indemnification, termination triggers, and dispute resolution. Parties should ensure that the agreement’s effective date, defined licensed assets, and performance milestones are precise to avoid ambiguity and to preserve enforceability under ESIGN and applicable state contract law.

Why a Clear License Agreement Matters

Using a clear, well-drafted License Agreement by and between Casi Pharmaceuticals Inc protects proprietary assets, defines commercial terms, and reduces litigation risk by allocating responsibilities. Precise language improves enforceability and supports regulatory compliance where electronic signatures and record retention are used.

Who Typically Prepares and Signs This Agreement

Common parties involved include licensors, licensees, in-house counsel, patent managers, and business development teams negotiating pharmaceutical intellectual property licenses.

Pharmaceutical companies licensing or acquiring drug compounds, formulations, or know-how.
Biotech startups assigning technology to strategic partners under milestone and royalty structures.
Legal and commercial teams drafting terms for confidentiality, indemnity, and commercialization rights.

Primary Signatory Roles

Licensor Counsel

Represents the company granting rights; typically prepares the license schedule, confirms ownership of claimed intellectual property, negotiates exclusivity and royalty terms, and signs on behalf of the corporate entity when authorized by board resolution or state corporate authority.

Licensee Director

Leads commercial evaluation and compliance; responsible for meeting diligence milestones, reporting sales, calculating royalties, and ensuring sublicense activity follows agreed limits and reporting obligations under the contract and coordinating audits with external counsel.

Essential Data Elements to Include

Effective Date: Enter as MM/DD/YYYY format.

Parties: Full legal names of each entity.

Licensed Assets: Describe patents, compounds, or know-how.

Scope: Territory, field of use, exclusivity.

Compensation: Royalties, milestones, upfront fees.

Termination Rights: Breach, insolvency, change of control.

Key Risks and Consequences of Drafting Errors

Ambiguous Scope: Leads to litigation risk

Incorrect Signatory: Can render agreement voidable

Missing IP Evidence: Ownership disputes and injunctions

Late Royalty Reporting: Financial penalties and audits

Noncompliance HIPAA: Breach fines if PHI involved

Improper Recordkeeping: Statutory retention violations

Common Drafting and Execution Mistakes

Failing to define licensed technology precisely, such as by omitting patent numbers, compound identifiers, or clear know-how descriptions, creates room for downstream disputes about what is covered.
Using vague payment terms like 'reasonable' or 'market rate' without formulas or examples causes disagreement and complicates audit and enforcement procedures.
Failing to record board or committee authorization for signers risks challenges to signatory authority and may trigger corporate governance defects.
Not aligning confidentiality duration and survival clauses with regulatory requirements can leave trade secrets unprotected after contract termination.

Step-by-Step: Completing the License Agreement

Follow this step-by-step sequence to complete and execute the License Agreement by and between Casi Pharmaceuticals Inc accurately.

01

Gather Documents: Collect patents, statements of invention, and corporate authorizations.
02

Draft Terms: Define scope, payments, milestones, and remedies.
03

Review Legal: Have counsel confirm assignment and export controls.
04

Execute: Sign, date, and distribute executed copies to parties.

Configure Digital Workflow for Secure Execution

Configure these workflow settings to prepare the agreement for secure electronic execution and tracking across parties.

Field	Configuration
Signature field placement and order	Choose sequential or parallel signing, set signer order.
Authentication methods and strength level	Email link, SMS code, or KBA; enable 2FA if required.
Document fields and conditional logic	Add signature, initials, dates, and conditional disclosure fields.
Audit trail retention and notifications	Capture timestamps, IPs, and email audit; set retention duration.

Technical Requirements and Integrations for eSigning

For eSigning and eSubmission, confirm platform requirements, authentication methods, and integrations before sending the License Agreement.

Browser Support: Use current Chrome, Edge, or Safari.
File Formats: PDF, Word DOCX supported.
Integrations: Salesforce, NetSuite, Google Workspace supported.

How Electronic Routing Typically Works

This is the typical routing process for electronically executing and delivering the license agreement to all parties.

Upload: Upload final agreement PDF or DOCX
Place Fields: Add signature, date, and initial fields for each signer.
Authenticate: Choose email link, SMS, or KBA per risk level.
Complete: Signed copies and audit certificate are distributed automatically.

Core Clauses to Check Before Signing

Core clauses and provisions commonly found in a professional license agreement are summarized below to help reviewers check for completeness before execution.

Grant

Specify whether rights are exclusive, sole, or non-exclusive; define permitted uses, field of use, geographic territory, and any time limits. Include sublicensing rights and reservation of retained rights.

Consideration

Detail upfront payments, milestone payments, running royalties, minimums, and reimbursement of patent prosecution or maintenance costs. State currency, payment schedule, and audit rights for verification.

Diligence

Set performance obligations, development timelines, commercialization benchmarks, and remedies for failure to meet diligence standards, including termination rights or conversion of exclusivity and reporting obligations to licensor.

Confidentiality

Define confidential information, permitted disclosures, duration of secrecy, exceptions, and required handling of materials. Include return or destruction obligations on termination and carve-outs for compelled disclosure.

Indemnity

Allocate responsibility for third-party claims, breaches, and product liability; include caps, notice and defense procedures, and cross-indemnification for IP infringement where applicable and specify control of litigation and settlement approval rights.

Termination

List termination for cause and convenience provisions, cure periods, post-termination rights, survival clauses for confidentiality, payment, indemnity, and procedures for wind-down and transfer of licenses.

Representative Use Cases and Outcomes

Real-world examples show how pharmaceutical licensors and licensees structure terms for development, commercialization, and IP enforcement in the License Agreement by and between Casi Pharmaceuticals Inc.

Biotech License

A small biotech licensed a novel compound to a larger pharmaceutical company with staged milestones and royalties tied to regulatory approvals.

Milestones triggered at IND and NDA approvals.
The parties defined clear IP assignments, prosecution cost sharing, and an audit right for royalties; they used electronic execution and retained signed records to meet recordkeeping and compliance obligations across jurisdictions.

Clinical Supply Deal

A pharmaceutical company licensed manufacturing know-how to a contract manufacturer to scale clinical supplies ahead of Phase II trials.

Included confidentiality and QA obligations.
Agreement allocated liability, required certificate of analysis for each batch, and set audit rights; signatures were captured electronically with detailed audit trails to support regulatory inspections.

eSignature Pricing and Feature Comparison for Agreement Execution

Compare common eSignature plan features and starting prices to assess options for executing and managing the License Agreement by and between Casi Pharmaceuticals Inc.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies	Varies	Varies	Varies
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

FAQs — Executing, Amending, and Retaining the Agreement

Answers to common questions about completing, signing, and retaining the License Agreement by and between Casi Pharmaceuticals Inc, with emphasis on electronic execution and compliance.

Need help? Contact support

Is an electronic signature legally valid?
Yes. Under the federal ESIGN Act (15 U.S.C. §7001) and state UETA laws, electronic signatures are generally enforceable provided intent, consent, attribution, and record retention are satisfied. Exceptions include wills, certain court filings, and other statutory exclusions listed by federal or state law.
Who may sign on behalf of a corporation?
Authorized officers or representatives with properly documented corporate authority may sign; execute under board resolution, corporate bylaws, or power of attorney where required. Verify signer authority in the fillable fields and retain evidence of authorization to avoid invalidation challenges.
Do I need a notary or witnesses?
Not normally for most license agreements, but notarization or witnesses may be required by state law for certain instrument types, or to record property interests. Check state-specific notarization and witness rules; use RON where permitted and retain recording as required.
How do electronic signatures satisfy HIPAA?
Electronic signatures can meet HIPAA requirements when used within HIPAA-compliant workflows and a Business Associate Agreement (BAA) is in place. Ensure encryption, access controls, and retention policies meet 45 CFR §164.530(j) requirements and that PHI disclosures are authorized.
What happens if a signer name is incorrect?
A mismatched or incorrect signer name can create enforceability questions or trigger requests for re-execution. Verify full legal names in the fillable fields, attach corporate authority if needed, and use signer authentication to strengthen attribution and reduce dispute risk.
How do I amend the agreement later?
Use a written amendment signed by authorized representatives referencing the original agreement and effective date. Document changes clearly, update schedules, and retain both the amendment and prior versions per retention policy to preserve auditability and demonstrate consent to modifications.

Explore Templates

Order Form Volume Card and Fundraiser Order Form Vinyl Liner Order and Measuring Form Quest Diagnostics Lab Order Form Restraining Order Form Air Force Order Form

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now